DNA

Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress

MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…

1 year ago

Bio-Path Holdings Reports Full Year 2022 Financial Results

Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, March 31, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),…

1 year ago

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days Strong graft…

1 year ago

Transplant Logistics Leader MediGO Issues Statement Welcoming HRSA Announcement on Organ Procurement and Transplantation Network Modernization Initiative

BALTIMORE, March 30, 2023 (GLOBE NEWSWIRE) -- MediGO, a Baltimore-based digital healthcare supply chain technology company focused on improving equity,…

1 year ago

Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs

VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the engagement of…

1 year ago

NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth

TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX)…

1 year ago

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate…

1 year ago

IMUNON Reports 2022 Financial Results and Provides Business Update

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…

1 year ago

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the…

1 year ago

Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study

- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts…

1 year ago